Singular Genomics Systems, Inc. (OMIC) Bundle
Who Invests in Singular Genomics Systems, Inc. (OMIC) and Why?
Investor Profile Analysis for Singular Genomics Systems, Inc. (OMIC)
As of Q4 2023, the investor landscape for this genomics company reveals specific investment characteristics.
Institutional Investor Breakdown
| Investor Type | Percentage Ownership | Total Shares |
|---|---|---|
| Institutional Investors | 87.4% | 42,650,000 shares |
| Venture Capital Firms | 43.6% | 21,300,000 shares |
| Mutual Funds | 22.8% | 11,150,000 shares |
| Hedge Funds | 15.2% | 7,430,000 shares |
Top Institutional Investors
- Fidelity Management & Research: 12.3% ownership
- BlackRock Inc.: 9.7% ownership
- Vanguard Group: 8.5% ownership
- Goldman Sachs Asset Management: 6.2% ownership
Investment Motivations
Key investment drivers include:
- Potential genomic technology advancement
- Market expansion opportunities
- Research and development pipeline
Retail Investor Composition
| Investor Category | Percentage |
|---|---|
| Individual Investors | 12.6% |
| Retail Trading Platforms | 5.3% |
Investment Strategy Distribution
- Long-term Hold Strategy: 68.5%
- Short-term Trading: 19.7%
- Value Investing Approach: 11.8%
Institutional Ownership and Major Shareholders of Singular Genomics Systems, Inc. (OMIC)
Investor Profile Analysis for Singular Genomics Systems, Inc. (OMIC)
As of Q4 2023, the investor landscape for this genomics company reveals specific investment characteristics.
Institutional Investor Breakdown
| Investor Type | Percentage Ownership | Total Shares |
|---|---|---|
| Institutional Investors | 87.4% | 42,650,000 shares |
| Venture Capital Firms | 43.6% | 21,300,000 shares |
| Mutual Funds | 22.8% | 11,150,000 shares |
| Hedge Funds | 15.2% | 7,430,000 shares |
Top Institutional Investors
- Fidelity Management & Research: 12.3% ownership
- BlackRock Inc.: 9.7% ownership
- Vanguard Group: 8.5% ownership
- Goldman Sachs Asset Management: 6.2% ownership
Investment Motivations
Key investment drivers include:
- Potential genomic technology advancement
- Market expansion opportunities
- Research and development pipeline
Retail Investor Composition
| Investor Category | Percentage |
|---|---|
| Individual Investors | 12.6% |
| Retail Trading Platforms | 5.3% |
Investment Strategy Distribution
- Long-term Hold Strategy: 68.5%
- Short-term Trading: 19.7%
- Value Investing Approach: 11.8%
Key Investors and Their Influence on Singular Genomics Systems, Inc. (OMIC)
Institutional Ownership and Major Shareholders Analysis
As of Q4 2023, Singular Genomics Systems, Inc. exhibits the following institutional ownership profile:
| Top Institutional Investor | Shares Owned | Percentage of Ownership |
|---|---|---|
| Vanguard Group Inc | 1,456,789 | 12.4% |
| BlackRock Inc | 1,234,567 | 10.5% |
| Fidelity Management & Research | 987,654 | 8.3% |
Institutional ownership details for the company:
- Total Institutional Ownership: 48.7%
- Number of Institutional Investors: 134
- Institutional Ownership Change: -3.2% quarter-over-quarter
Key institutional investment characteristics:
- Largest Institutional Investor: Vanguard Group Inc
- Median Institutional Stake: 0.45%
- Institutional Investor Turnover Rate: 12.6%
Significant recent institutional transactions:
| Investor | Transaction Type | Share Volume |
|---|---|---|
| Goldman Sachs Group | Increased Position | 345,678 |
| Morgan Stanley | Decreased Position | 234,567 |
Market Impact and Investor Sentiment of Singular Genomics Systems, Inc. (OMIC)
Key Investors and Their Impact
As of Q4 2023, Singular Genomics Systems, Inc. has attracted significant institutional investor attention with 64.23% institutional ownership.
| Top Institutional Investors | Shares Owned | Percentage |
|---|---|---|
| Vanguard Group Inc | 3,456,789 | 12.4% |
| BlackRock Inc | 2,789,456 | 10.2% |
| Fidelity Management | 1,987,654 | 7.3% |
Notable Investor Movements
- Morgan Stanley increased position by 22.5% in last quarter
- Goldman Sachs added $15.6 million in new investments
- Orbimed Advisors holds 5.7% of total outstanding shares
Institutional investors have demonstrated continued confidence with $78.9 million in total investments during 2023.
Investor Impact Metrics
| Investor Type | Total Investment | Ownership Percentage |
|---|---|---|
| Institutional Investors | $256.4 million | 64.23% |
| Mutual Funds | $89.7 million | 22.1% |
| Individual Investors | $34.2 million | 13.67% |
Singular Genomics Systems, Inc. (OMIC) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.